Accelrys Materials Studio Enhances Modeling and Simulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelrys Materials Studio Enhances Modeling and Simulation

Equipment and Processing Report

Accelrys Materials Studio 7.0 modeling and simulation environment contains enhancements in quantum mechanics, classical simulation, usability, visualization, and collaboration to enable scientists to engineer better performing and more cost-effective materials. The software enables scientists to perform highly complex materials research using multi-scale simulation methods to construct, manipulate, and view models of molecules, crystalline materials, surfaces, polymers, and mesoscale structures. An improved solubility-property prediction provides better understanding of solvation properties. By understanding and predicting the relationships between a material's atomic and molecular structure and its properties and behaviors, materials scientists can develop better performing materials of all types faster and more efficiently than with test and experimentation alone.

Source: Accelrys

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here